The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19

Chia Siang Kow; Syed Shahzad Hasan

doi:10.1002/oby.22976

The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19

Chia Siang Kow, Syed Shahzad Hasan

Research output: Contribution to journal › Letter › peer-review

2 Citations (Scopus)

Abstract

Individuals with chronic obstructive pulmonary disease (COPD) have long been identified to have an elevated serum level of angiotensin‐converting enzyme 2 (ACE2), the cellular entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The newest discoveries by Higham et al. (1) were the increased ACE2 expression in the bronchial epithelium of overweight COPD patients compared to their non‐overweight counterparts.

Original language	English
Pages (from-to)	2035
Number of pages	1
Journal	Obesity
Volume	28
Issue number	11
Early online date	21 Jul 2020
DOIs	https://doi.org/10.1002/oby.22976
Publication status	Published - 1 Nov 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/oby.22976Licence: Unspecified

Cite this

@article{4d0564af8e564b8aac35d9dc2f1e23e6,

title = "The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19",

abstract = "Individuals with chronic obstructive pulmonary disease (COPD) have long been identified to have an elevated serum level of angiotensin‐converting enzyme 2 (ACE2), the cellular entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The newest discoveries by Higham et al. (1) were the increased ACE2 expression in the bronchial epithelium of overweight COPD patients compared to their non‐overweight counterparts.",

keywords = "COVID-19, Telmisartan, COPD, Overweight",

author = "Kow, {Chia Siang} and Hasan, {Syed Shahzad}",

year = "2020",

month = nov,

day = "1",

doi = "10.1002/oby.22976",

language = "English",

volume = "28",

pages = "2035",

journal = "Obesity",

issn = "1930-7381",

publisher = "John Wiley and Sons Inc.",

number = "11",

}

TY - JOUR

T1 - The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19

AU - Kow, Chia Siang

AU - Hasan, Syed Shahzad

PY - 2020/11/1

Y1 - 2020/11/1

N2 - Individuals with chronic obstructive pulmonary disease (COPD) have long been identified to have an elevated serum level of angiotensin‐converting enzyme 2 (ACE2), the cellular entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The newest discoveries by Higham et al. (1) were the increased ACE2 expression in the bronchial epithelium of overweight COPD patients compared to their non‐overweight counterparts.

AB - Individuals with chronic obstructive pulmonary disease (COPD) have long been identified to have an elevated serum level of angiotensin‐converting enzyme 2 (ACE2), the cellular entry receptor for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The newest discoveries by Higham et al. (1) were the increased ACE2 expression in the bronchial epithelium of overweight COPD patients compared to their non‐overweight counterparts.

KW - COVID-19

KW - Telmisartan

KW - COPD

KW - Overweight

UR - http://www.scopus.com/inward/record.url?scp=85091296008&partnerID=8YFLogxK

U2 - 10.1002/oby.22976

DO - 10.1002/oby.22976

M3 - Letter

C2 - 32692903

SN - 1930-7381

VL - 28

SP - 2035

JO - Obesity

JF - Obesity

IS - 11

ER -

The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Study says inhalers OK to use amid COVID-19 concerns

Cite this

The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Press/Media

Study says inhalers OK to use amid COVID-19 concerns

Cite this